Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. (Q45919430)
Jump to navigation
Jump to search
scientific article published in August 2009
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. |
scientific article published in August 2009 |
Statements
1 reference
Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. (English)
1 reference
Kazuyuki Tsujino
1 reference
Tomoya Kawaguchi
1 reference
Akihito Kubo
1 reference
Nana Aono
1 reference
Keiko Nakao
1 reference
Yasuhiro Koh
1 reference
Kazunobu Tachibana
1 reference
Shun-Ichi Isa
1 reference
Minoru Takada
1 reference
Takayasu Kurata
1 reference
1 August 2009
1 reference
4
1 reference
8
1 reference
994-1001
1 reference